Could an 'Exercise-in-a-Pill' replace workouts for heart failure?
NCT ID NCT05696652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study from Stanford University is looking at what happens inside the body when people with heart failure exercise. Researchers will measure thousands of proteins in the blood before and after a single workout, and again after a 12-week cardiac rehab program. By comparing these protein changes between those who exercise and those who wait, they hope to find molecules that could one day be turned into medicines that mimic exercise's benefits.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- exercise (acute treadmill session and 12-week cardiac rehabilitation)
- What this could lead to
- If successful, this could identify key proteins that change with exercise, pointing toward new drug targets that mimic exercise benefits for heart failure patients.
- What could go wrong
- This is an early exploratory study with only 90 participants. It measures protein changes, not clinical outcomes, so it may not lead to any new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2024
- Expected to finish
-
Apr 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 89 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 18-89 * Patients must carry a diagnosis of heart failure with ejection fraction \< 40% * Be willing to participate in cardiac rehabilitation, and not already done so in the last year * Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration * Must be able to exercise on a treadmill Exclusion Criteria: * Inability to complete CPET or participate in CR (verbal/chart) * Syncope during CPET within the last 6 mos, sustained VT on CPET, hemodynamically significant arrhythmia during CPET (verbal/chart) * BMI \>= 38 (verbal/chart) * History of a bleeding disorder or clotting abnormality (verbal/chart) * Clinical diagnosis of severe Chronic Obstructive Pulmonary Disease (COPD) (verbal/chart) * History of malignancy not considered in remission (verbal/chart) * Cirrhosis (verbal/chart) * Thyroid disease (verbal/chart) * Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory within the last 1 year * Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting * Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment * Cancer (verbal/chart) * History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years * Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months * Chronic active or latent infection (verbal/chart) * Active or latent infections requiring chronic antibiotic or anti-viral treatment * Chronic active infection whether on chronic antimicrobials or not * Human Immunodeficiency Virus * Active hepatitis B or C undergoing antiviral therapy * Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded * Tobacco (verbal/chart) * Current smokers: any tobacco or e-cigarette/e-nicotine products * Former smokers: Stopped smoking \<6 months at time of screening * Not be pregnant or lactating in the last 12 months, or planning to become pregnant for the next 4 months. Not be post-partum during the last 12 months. (verbal/chart) * Metabolic bone disease (self-report): History of non-traumatic fracture from a standing height or less. Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen. (verbal/chart) * Diabetes (self-report and screening), which includes: i) treatment with any insulin or ii) A1c \>=8.0 (screening). (verbal/chart) * Chronic renal insufficiency (screening): estimated glomerular filtration rate \<30 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation. (verbal/chart) * Individuals receiving any active treatment for autoimmune disorders (including monoclonal antibodies) within the last 6 months. (verbal/chart) * Alcohol consumption: i) more than 7 drinks per week for women and more than 14 drinks per week for men; ii) history of binge drinking. (verbal/chart) * Any individual engaging in night shift work in the last 6 months. * Hospitalization for any psychiatric condition within one year (verbal/chart) * Any musculoskeletal or ligamentous injury, amputation or congenital neurological defect that, in the opinion of the team clinician, would negatively impact or mitigate participation in and completion of the protocol. (verbal/chart) * Mental incapacity and/or cognitive impairment on the part of the participant that would inhibit adequate understanding of or cooperation with the study protocol * Other (clinician judgment) * Genetic metabolic disorders that could affect metabolomic results (e.g., phenylketonuria) * Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, metabolic, or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol * Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol * Medication exclusions (chart review) * Androgenic anabolic steroids, antiestrogens, antiandrogens * Growth hormone, insulin like growth factor, growth hormone releasing hormone * Insulin of any type used regularly * Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise induced muscle hypertrophy * Psychiatric * Chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines; short-acting non-benzodiazepine sedative-hypnotics are allowed * Two or more drugs for depression * Mood stabilizers * Antiepileptic drugs * Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs * Anti-psychotic drugs * Narcotics and narcotic receptor agonists * Chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc) for any reason * High-potency topical steroids if ≥10% of surface area using rule of 9s * Continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention * Monoclonal antibodies * Anti-rejection medications/immune suppressants * Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Stanford Health Care
RECRUITINGStanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a handheld ultrasound help clinics spot heart failure sooner?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can AI read heart ultrasounds as well as trained sonographers?